Ginecología Oncológica & Enfermedades Mamarias - Dr. Carlos Urrutia Romero

  • Casa
  • Peru
  • Pueblo Libre
  • Ginecología Oncológica & Enfermedades Mamarias - Dr. Carlos Urrutia Romero

Ginecología Oncológica & Enfermedades Mamarias - Dr. Carlos Urrutia Romero Médico especialista en la prevención diagnóstico y tratamiento enfermedades Oncológicas ginecológicas

14/02/2026

Now available ahead of print: Elimination of the Black Box Warning on Menopausal Hormone Therapy. Always find the latest at https://buff.ly/Whq5yiR

11/02/2026

📌 SEUD Plenary Session 5 will explore cancer risks on endometriosis and uterine disorder patients. A key session to enhance your clinical expertise and improve patient care.
Join our experts on Friday, April 10th at 14:15 to dive into:
🔎 Endometriosis phenotypes and ovarian cancer with Pere N Barri
🔎 Endometrial cancer, EIN and atypical hyperplasia: fertility-sparing surgery with Franscesco Fanfani
🔎 Relationship between uterine fibroids, adenomyosis and uterine sarcoma with Eva Roser
🔎 Emerging biomarkers in uterine neoplasms with Guillaume Beinse

You're still on time to book your seat and join us in Frankfurt from April 9th to 11th!

Register now ➡ https://swll.to/SEUD-2026-Registrations

09/02/2026

Recovery after low-impact laparoscopic hysterectomy: a randomized controlled clinical trial https://ow.ly/B3aV50Yb7uE

28/01/2026

EDITOR'S PICK: Article of the Month!

"For patients with uterine cancer, comorbidity prevalence and comorbidity index scores varied significantly by race and ethnicity and were highest among non-Hispanic Black patients. Quantifying the distribution of comorbidities allows us to anticipate, statistically, how the accrual of racially minoritized populations may be hampered by individual comorbidity eligibility criteria. We suggest that quantified measures be used to plan both trial eligibility criteria and targeted recruitment in the setting of known eligibility disparities. Strategically planned and culturally appropriate equity efforts are important in today’s cancer care landscape due to funding and policy changes that influence diversity and inclusion efforts."

Listen to Dr. Oluloro explain her team's findings on the Green Room podcast wherever you find your other favorite podcasts, or at: https://journals.lww.com/greenjournal/pages/podcastepisodes.aspx?podcastid=9

Full-length article available to read for FREE at: https://journals.lww.com/greenjournal/fulltext/2026/02000/association_between_comorbidity_and_clinical_trial.15.aspx?context=featuredarticles&collectionid=5

15/01/2026

🔊 infection is extremely common, yet the stigmas around sexual health and cancer persist. Fear, shame, ignorance can cause delays in seeking care and late diagnosis. No one should suffer because of a lack of understanding. Share these facts.

Learn more here: https://igcs.org/cervical-cancer-elimination/

15/01/2026

The : Levonorgestrel-releasing IUD as single therapy for inoperable, early stage and

💡 https://bit.ly/3NbMavU

06/01/2026

✨
ctDNA 🧬 emerges as a promising non-invasive biomarker🔬for detection, with strong performance in early-stage disease.

✴️ A step forward beyond CA125?

💡 https://bit.ly/49osPPp

28/12/2025

Discover the Oncofertility special section in the IJGO, focused on oncofertility cryopreservation—a critical and growing field that bridges oncology and reproductive medicine.

This new collection of papers, curated by FIGO Committee on Reproductive Medicine, Endocrinology and Infertility, sets out best clinical practice guidance for preserving fertility in patients diagnosed with cancer, especially during their reproductive years.

Read more: https://www.figo.org/news/figo-launches-oncofertility-best-practices-preserving-fertility-cancer-patients-0

20/12/2025

MIS vs. Open Surgery for recurrent 🏥

✅ Feasible: 97.3% complete resection rate with MIS.
✅ Gentler: Less blood loss & faster recovery time.
✅ Safe: Survival rates were comparable to open surgery.

📌 https://bit.ly/4oVvQwv

16/12/2025

Las autoridades sanitarias de Estados Unidos han ampliado la aprobación de un fármaco muy debatido destinado a aumentar la libido femenina, tras afirmar que la píldora que se toma una vez al día ahora puede ser tomada por mujeres mayores de 65 años.

Dirección

Avenida Brasil 271 , Edificio Qualis , Consultorio 922
Pueblo Libre
051

Teléfono

+51960378264

Página web

Notificaciones

Sé el primero en enterarse y déjanos enviarle un correo electrónico cuando Ginecología Oncológica & Enfermedades Mamarias - Dr. Carlos Urrutia Romero publique noticias y promociones. Su dirección de correo electrónico no se utilizará para ningún otro fin, y puede darse de baja en cualquier momento.

Contacto El Consultorio

Enviar un mensaje a Ginecología Oncológica & Enfermedades Mamarias - Dr. Carlos Urrutia Romero:

Atajos

Compartir

Categoría